These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

427 related articles for article (PubMed ID: 23418312)

  • 21. Approaches targeting the FGF-FGFR system: a review of the recent patent literature and associated advanced therapeutic agents.
    Herbert C; Lassalle G; Alcouffe C; Bono F
    Pharm Pat Anal; 2014; 3(6):585-612. PubMed ID: 25489913
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Fibroblast growth factor receptors, developmental corruption and malignant disease.
    Kelleher FC; O'Sullivan H; Smyth E; McDermott R; Viterbo A
    Carcinogenesis; 2013 Oct; 34(10):2198-205. PubMed ID: 23880303
    [TBL] [Abstract][Full Text] [Related]  

  • 23. AZD4547: an orally bioavailable, potent, and selective inhibitor of the fibroblast growth factor receptor tyrosine kinase family.
    Gavine PR; Mooney L; Kilgour E; Thomas AP; Al-Kadhimi K; Beck S; Rooney C; Coleman T; Baker D; Mellor MJ; Brooks AN; Klinowska T
    Cancer Res; 2012 Apr; 72(8):2045-56. PubMed ID: 22369928
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Fibroblast growth factor signaling and inhibition in non-small cell lung cancer and their role in squamous cell tumors.
    Salgia R
    Cancer Med; 2014 Jun; 3(3):681-92. PubMed ID: 24711160
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Intedanib, a triple kinase inhibitor of VEGFR, FGFR and PDGFR for the treatment of cancer and idiopathic pulmonary fibrosis.
    Antoniu SA; Kolb MR
    IDrugs; 2010 May; 13(5):332-45. PubMed ID: 20432191
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro biological characterization and antiangiogenic effects of PD 166866, a selective inhibitor of the FGF-1 receptor tyrosine kinase.
    Panek RL; Lu GH; Dahring TK; Batley BL; Connolly C; Hamby JM; Brown KJ
    J Pharmacol Exp Ther; 1998 Jul; 286(1):569-77. PubMed ID: 9655904
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting fibroblast growth factor receptors blocks PI3K/AKT signaling, induces apoptosis, and impairs mammary tumor outgrowth and metastasis.
    Dey JH; Bianchi F; Voshol J; Bonenfant D; Oakeley EJ; Hynes NE
    Cancer Res; 2010 May; 70(10):4151-62. PubMed ID: 20460524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fibroblast Growth Factor Receptor Signaling in Skin Cancers.
    Czyz M
    Cells; 2019 Jun; 8(6):. PubMed ID: 31167513
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Targeting Drugs Against Fibroblast Growth Factor(s)-Induced Cell Signaling.
    Agrawal S; Maity S; AlRaawi Z; Al-Ameer M; Kumar TKS
    Curr Drug Targets; 2021; 22(2):214-240. PubMed ID: 33045958
    [TBL] [Abstract][Full Text] [Related]  

  • 30. FGF signaling network in the gastrointestinal tract (review).
    Katoh M; Katoh M
    Int J Oncol; 2006 Jul; 29(1):163-8. PubMed ID: 16773196
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Future applications of FGF/FGFR inhibitors in cancer.
    Ghedini GC; Ronca R; Presta M; Giacomini A
    Expert Rev Anticancer Ther; 2018 Sep; 18(9):861-872. PubMed ID: 29936878
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of the fibroblast growth factor receptor (FGFR) pathway: the current landscape and barriers to clinical application.
    Chae YK; Ranganath K; Hammerman PS; Vaklavas C; Mohindra N; Kalyan A; Matsangou M; Costa R; Carneiro B; Villaflor VM; Cristofanilli M; Giles FJ
    Oncotarget; 2017 Feb; 8(9):16052-16074. PubMed ID: 28030802
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Structural Alterations in Human Fibroblast Growth Factor Receptors in Carcinogenesis.
    Mikhaylenko DS; Alekseev BY; Zaletaev DV; Goncharova RI; Nemtsova MV
    Biochemistry (Mosc); 2018 Aug; 83(8):930-943. PubMed ID: 30208830
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Roles of fibroblast growth factor receptors in carcinogenesis.
    Haugsten EM; Wiedlocha A; Olsnes S; Wesche J
    Mol Cancer Res; 2010 Nov; 8(11):1439-52. PubMed ID: 21047773
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Current strategies for inhibiting FGFR activities in clinical applications: opportunities, challenges and toxicological considerations.
    Ho HK; Yeo AH; Kang TS; Chua BT
    Drug Discov Today; 2014 Jan; 19(1):51-62. PubMed ID: 23932951
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Fibroblast Growth Factor Receptor (FGFR): A New Target for Non-small Cell Lung Cancer Therapy.
    Biello F; Burrafato G; Rijavec E; Genova C; Barletta G; Truini A; Coco S; Bello MG; Alama A; Boccardo F; Grossi F
    Anticancer Agents Med Chem; 2016; 16(9):1142-54. PubMed ID: 26845137
    [TBL] [Abstract][Full Text] [Related]  

  • 37. FGFR-TKI resistance in cancer: current status and perspectives.
    Yue S; Li Y; Chen X; Wang J; Li M; Chen Y; Wu D
    J Hematol Oncol; 2021 Feb; 14(1):23. PubMed ID: 33568192
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Recent advances of dual FGFR inhibitors as a novel therapy for cancer.
    Liang Q; Wang J; Zhao L; Hou J; Hu Y; Shi J
    Eur J Med Chem; 2021 Mar; 214():113205. PubMed ID: 33556787
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Disruption of fibroblast growth factor signal pathway inhibits the growth of synovial sarcomas: potential application of signal inhibitors to molecular target therapy.
    Ishibe T; Nakayama T; Okamoto T; Aoyama T; Nishijo K; Shibata KR; Shima Y; Nagayama S; Katagiri T; Nakamura Y; Nakamura T; Toguchida J
    Clin Cancer Res; 2005 Apr; 11(7):2702-12. PubMed ID: 15814652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Targeting FGF receptors in colorectal cancer: from bench side to bed side.
    Abdel-Rahman O
    Future Oncol; 2015; 11(9):1373-9. PubMed ID: 25952783
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.